[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100586261":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":11,"centralContacts":28,"locations":34,"responsibleParty":76,"collaborators":11,"id":78,"slug":79,"hasResults":80,"nctId":81,"briefTitle":82,"officialTitle":83,"acronym":84,"eligibilityCriteria":85,"healthyVolunteers":80,"sex":86,"minAge":87,"maxAge":88,"enrollmentInfo":89,"targetDuration":11,"studyType":92,"phases":93,"briefSummary":95,"conditions":96,"keywords":98,"overallStatus":102,"whyStopped":11,"lastUpdateSubmitDate":103,"lastUpdatePostDateStruct":104,"startDateStruct":107,"completionDateStruct":109,"leadSponsor":111,"locationsCount":112},{"fullName":5,"class":6},"Indira IVF Hospital Pvt Ltd","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Group A","ACTIVE_COMPARATOR",null,[13],"Drug: GnRH agonist downregulation",{"label":15,"type":10,"description":11,"interventionNames":16},"Group B",[17],"Drug: GnRH agonist and Letrozole",[19,24],{"type":20,"name":21,"description":22,"armGroupLabels":23,"otherNames":11},"DRUG","GnRH agonist downregulation","Triptorelin Acetate 3.75mg for two consecutive dosage at 30 days interval",[9],{"type":20,"name":25,"description":26,"armGroupLabels":27,"otherNames":11},"GnRH agonist and Letrozole","Triptorelin Acetate 3.75mg for two consecutive dosages at 30 days interval) + Letrozole (5 mg once daily for a total of 21 days during the second depot - letrozole stops when Estrogen priming starts",[15],[29],{"name":30,"role":31,"phone":32,"phoneExt":11,"email":33},"Taruna Jhamb, MD","CONTACT","+91 9799035674","centerhead.udaipur@indiraivf.in",[35],{"facility":36,"status":11,"city":37,"state":38,"zip":39,"country":40,"countryCode":41,"cosmosGeoPoint":42,"geoPoint":47,"contacts":48},"Indira IVF Pvt Hospital","Udaipur","Rajasthan","313001","India","IN",{"type":43,"coordinates":44},"Point",[45,46],73.71346,24.58584,{"lat":46,"lon":45},[49,52,54,57,58,60,62,64,66,68,70,72,74],{"name":50,"role":31,"phone":11,"phoneExt":11,"email":51},"Vipin Chandra, DGO","drvipinchandra@indiraivf.in",{"name":30,"role":53,"phone":11,"phoneExt":11,"email":11},"PRINCIPAL_INVESTIGATOR",{"name":55,"role":56,"phone":11,"phoneExt":11,"email":11},"Peter Humaidan, DMSc","SUB_INVESTIGATOR",{"name":50,"role":56,"phone":11,"phoneExt":11,"email":11},{"name":59,"role":56,"phone":11,"phoneExt":11,"email":11},"Snehadarshani Karnath, MD",{"name":61,"role":56,"phone":11,"phoneExt":11,"email":11},"Yasha Pandey, MD",{"name":63,"role":56,"phone":11,"phoneExt":11,"email":11},"Akanksha Jangid, MD",{"name":65,"role":56,"phone":11,"phoneExt":11,"email":11},"Pawan Yadav, MD",{"name":67,"role":56,"phone":11,"phoneExt":11,"email":11},"Pooja Shinde, DNB",{"name":69,"role":56,"phone":11,"phoneExt":11,"email":11},"Nisha Tiwari, DNB",{"name":71,"role":56,"phone":11,"phoneExt":11,"email":11},"Tanu Batra, DNB",{"name":73,"role":56,"phone":11,"phoneExt":11,"email":11},"Amol Lunkad, MD",{"name":75,"role":56,"phone":11,"phoneExt":11,"email":11},"Rinoy Sreedharan, MD",{"type":77,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100586261","fet-in-adenomyosis-100586261",false,"NCT06913075","FET in Adenomyosis","Is GnRH Agonist Plus Letrozole a Better Choice Than GnRH Agonist Alone in Adenomyosis Cases Undergoing Frozen Embryo Transfer?","ADY","Inclusion Criteria:\n\nDiagnosis of adenomyosis confirmed via transvaginal ultrasound as per MUSA criteria History of infertility requiring frozen embryo transfer (FET). Availability of at least one good-quality frozen embryo for transfer\n\nExclusion Criteria:\n\nBMI ≥ 30 kg\u002Fm2 Presence of endocrine disorders; (uncontrolled diabetes mellitus, \u002F hyperprolactinemia, thyroid dysfunction, Congenital adrenal hyperplasia, Cushing syndrome, or polycystic ovary syndrome Previous major uterine surgery Gestational carrier Fertility preservation","FEMALE","21 Years","42 Years",{"count":90,"type":91},700,"ESTIMATED","INTERVENTIONAL",[94],"NA","Purpose of the Study:\n\nTo compare the effectiveness of GnRH agonist downregulation alone versus GnRH agonist combined with letrozole in improving pregnancy outcomes in women with adenomyosis undergoing frozen embryo transfer (FET).\n\nResearch Question:\n\nIs the combined use of GnRH agonist and letrozole more effective than GnRH agonist downregulation alone in achieving better ongoing pregnancy rates in adenomyosis cases undergoing FET?\n\nHypothesis:\n\nNull Hypothesis (H₀): The combined use of GnRH agonist and letrozole is not more effective than GnRH agonist downregulation alone in achieving a higher ongoing pregnancy rate in adenomyosis cases undergoing FET.\n\nStudy Outcomes:\n\nPrimary Outcome: Ongoing pregnancy rate at 12 weeks of gestation.",[97],"Adenomyosis",[99,97,100,101],"Frozen embryo transfer","ongoing pregnancy rate","live birth rate","NOT_YET_RECRUITING","2026-01-23",{"date":105,"type":106},"2026-01-26","ACTUAL",{"date":108,"type":91},"2026-06-25",{"date":110,"type":91},"2026-12-23",{"name":5,"class":6},1]